Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Cancer Research

• Publication date

  1983-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 6831430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors influencing the in situ activation of macrophages by liposomes containing muramyl dipeptide

  1983cited by this paper
• Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.

  1982cited by this paper
• Evidence for the clonal origin of spontaneous metastases.

  1982cited by this paper
• Immunomodulation by muramyl peptides: Recent developments

  1982cited by this paper
• Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages.

  1981cited by this paper
• The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.

  1981cited by this paper
• Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases.

  1981cited by this paper
• In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

  1981cited by this paper
• Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

  1981cited by this paper
• Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient.

  1980cited by this paper
• Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines.

  1980cited by this paper
• Biological Variability within Murine Neoplasms1

  1980cited by this paper
• The pathogenesis of cancer metastasis

  1980cited by this paper
• Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.

  1980cited by this paper
• Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide

  1980cited by this paper
• Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.

  1980cited by this paper
• Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

  1979cited by this paper
• Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.

  1979cited by this paper
• Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.

  1979cited by this paper
• Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators.

  1979cited by this paper
• Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.

  1979cited by this paper
• Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells

  1978cited by this paper
• Recognition and destruction of target cells by tumoricidal macrophages.

  1978cited by this paper
• Macrophage stimulation by bacterial lipopolysaccharides. II. Evidence for differentiation signals delivered by lipid A and by a protein rich fraction of lipopolysaccharides

  1978cited by this paper
• Tumor heterogeneity and the biology of cancer invasion and metastasis.

  1978cited by this paper
• In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics.

  1978cited by this paper
• Macrophage tumor killing: influence of the local environment.

  1977cited by this paper
• Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

  1975cited by this paper
• Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

  1974cited by this paper
• In Vitro Destruction of Tumor Cells by Human Monocyte 1

  1974cited by this paper
• In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

  1973cited by this paper
• Mechanism of Immunologically Specific Killing of Tumour Cells by Macrophages

  1972cited by this paper

• Tumour‐Associated Macrophages in Oral Squamous Cell Carcinoma

  2025cites this paper
• Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

  2022cites this paper
• State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma

  2021cites this paper
• Advancing therapy for osteosarcoma

  2021cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020cites this paper
• Signature based on immune-related LncRNA can predict overall survival of osteosarcoma patients

  2020cites this paper
• Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.

  2020cites this paper
• Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment

  2020cites this paper
• Bacterium‐Mimicking Vector with Enhanced Adjuvanticity for Cancer Immunotherapy and Minimized Toxicity

  2019cites this paper
• Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

  2018cites this paper
• IMPROVING NK CELL THERAPY FOR OSTEOSARCOMA

  2017cites this paper
• L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.

  2016cites this paper
• Osteosarcoma Overview

  2016cites this paper
• THE ROLE OF AUTOPHAGY IN THE SENSITIVITY OF OSTEOSARCOMA CELLS TO GEMCITABINE TREATMENT

  2015cites this paper
• Complexation-triggerable liposome mixed with silk protein and chitosan

  2015cites this paper
• Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

  2014cites this paper
• Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.

  2014cites this paper
• Natural killer cell therapy and aerosol interleukin‐2 for the treatment of osteosarcoma lung metastasis

  2014cites this paper
• Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

  2014cites this paper
• COMBINATION THERAPY WITH AEROSOL IL-2 AND NK CELLS FOR THE TREATMENT OF OSTEOSARCOMA LUNG METASTASIS

  2014cites this paper
• Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?

  2014cites this paper
• Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.

  2014cites this paper
• Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments

  2014cites this paper
• Innate immune responses of natural killer cells and macrophages against bone sarcomas : towards cellular immunotherapy

  2014cites this paper
• Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

  2014cites this paper
• Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression

  2013cites this paper
• Targeted inhibition of cancer-inflammation

  2012cites this paper
• Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

  2012cites this paper
• New treatment options for nonmetastatic osteosarcoma: focus on mifamurtide in adolescents

  2012cites this paper
• Synthesis and Biological Applications of Glycoconjugates

  2012cites this paper
• Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cites this paper
• A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers

  2012cites this paper
• Targeting Interleukin-11 Receptor a-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases

  2011cites this paper
• Mifamurtide for the treatment of nonmetastatic osteosarcoma

  2011cites this paper
• Mifamurtide in osteosarcoma--a practical review.

  2010cites this paper
• Mifamurtide

  2010cites this paper
• Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

  2009cites this paper
• Macrophages and cancer.

  2008cites this paper
• Human Cancer

  2006cites this paper
• Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

  2006cites this paper
• In Vitro and in Vivo Effect of Doxorubicin Combined with Liposome-encapsulated Muramyl Tripeptide on Canine Monocyte Activation 1

  2006cites this paper
• Eradication of Hepatic Métastasesof Carcinoma H-59 by Combination Chemoimmunotherapy with Liposomal Muramyl Tripeptide, 5-Fluorouracil, and Leucovorin1

  2006influential citation
• NONSELECTIVE LYSIS OF TUMOR CELLS BY MACROPHAGES Cell Cultures

  2006cites this paper
• In Vitro and in Vivo Effect of Doxorubicin Combined with Liposome-encapsulated Muramyl Tripeptide on Canine Monocyte Activation1

  2006cites this paper
• NonselectiveDestructionof MurineNeoplastiaCells by SyngeneicTumoricidal Macrophages 1

  2006cites this paper
• Cancer therapy-induced immune modulation.

  2005cites this paper
• Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

  2005influential citation
• Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine

  2005cites this paper
• Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels

  2005cites this paper
• Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide

  2004cites this paper
• A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state

  2004cites this paper
• Role of culture supernatant of cytotoxic/cytostatic macrophages in activation of murine resident peritoneal macrophages

  2004cites this paper
• Emerging cancer-targeted therapies.

  2002cites this paper
• Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.

  2000cites this paper
• Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer

  2000cites this paper
• Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.

  1999cites this paper
• Lipophilic drug derivatives in liposomes

  1998cites this paper
• Liposomal Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Resectable Melanoma in Patients Who Were at High Risk for Relapse: An Update

  1998cites this paper
• Activation of cytokine production, tumoricidal properties, and tyrosine phosphorylation of MAPKs in human monocytes by a new synthetic lipopeptide, JBT3002

  1998cites this paper
• Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators.

  1998cites this paper
• Polyethylenimine-mediated transfection of human monocytes with the IFN-γ gene: an approach for cancer adoptive immunotherapy

  1998cites this paper
• Osteosarcoma.

  1997cites this paper
• Osteosarcoma.

  1997cites this paper
• The effect of autologous tumour vaccine on benzo-a-pyrene induced squamous cell carcinoma of skin in mice

  1997cites this paper
• Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives.

  1996cites this paper
• Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin.

  1996cites this paper
• Liposome-encapsulated Muramyl Tripeptide Phosphatidylethanolamine for the Treatment of Feline Mammary Adenocarcinoma-A Multicenter Randomized Double-blind Study

  1995cites this paper
• Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.

  1995cites this paper
• Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

  1995cites this paper
• Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

  1995cites this paper
• Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma

  1995cites this paper
• Repeated Intravenous Administration of Liposome-Encapsulated Muramyl Tripeptide-Phosphatidyl-Ethanolamine Diminishes Cytotoxic Potential of Subpopulations of Rat Liver Macrophages

  1995cites this paper
• Influence of liposomal muramyl tripeptide phosphatidylethanolamine on the changes of nucleic acids in the blood and hemopoietic tissues of irradiated mice.

  1995cites this paper
• Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

  1995cites this paper
• Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE.

  1995cites this paper
• Role of 5'-lipoxygenase metabolites in the activation of peritoneal macrophages for tumoricidal function.

  1995cites this paper
• Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.

  1995cites this paper
• Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis

  1994cites this paper
• In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.

  1994cites this paper
• Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.

  1994cites this paper
• Tumor cytotoxicity and production of interleukin-1 and tumor necrosis factor from blood monocytes of cervical carcinoma patients.

  1994cites this paper
• Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.

  1994cites this paper
• Induction of Serum Tumor Necrosis Factor-alpha and Interleukin-6 Activity by Liposome-encapsulated Muramyl Tripeptide-phosphatidylethanolamine (L-MTP-PE) in Normal Cats

  1994cites this paper
• Effect of Liposome-Muramyl Tripeptide Combined with Recombinant Canine Granulocyte Colony-Stimulating Factor on Canine Monocyte Activity

  1994cites this paper
• Liposomes in drug targeting.

  1994cites this paper
• Liposomal MTP-PE

  1994cites this paper
• Influence of synthetic adjuvants on nonspecific resistance to infections.

  1994cites this paper
• Therapy of cancer metastasis by systemic activation of macrophages.

  1994cites this paper
• The biologic window for chimeric l6 radioimmunotherapy

  1994cites this paper
• Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients.

  1994cites this paper
• In Vitro Synergic Effect of Interferon Gamma Combined with Liposomes Containing Muramyl Tripeptide on Human Monocyte Cytotoxicity Against Fresh Allogeneic and Autologous Tumor Cells

  1994cites this paper
• Carbohydrate-mediated liposomal targeting and drug delivery

  1994cites this paper
• Deacylation-reacylation cycle: a possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats.

  1993cites this paper
• Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide

  1993cites this paper
• Muramyl Peptides Augment the In Vitro and In Vivo Cytostatic Activity of Canine Plastic-Adherent Mononuclear Cells Against Canine Osteosarcoma Cells

  1993cites this paper
• Activation of cytolytic activity in peripheral blood

  1993cites this paper
• Cytokine Production and Immune Cell Activation in Melanoma Patients Treated with Liposomal Muramyl Tripeptide (CGP 19835A Lipid)1

  1993cites this paper
• Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells.

  1993cites this paper
• Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.

  1993cites this paper
• In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.

  1993cites this paper